logo for event: Spring 2025 Cancer Policy Roundtable | March 27

Cancer Policy Roundtable

March 27, 2025 | 8:30 AM ET – 3:00 PM ET

Four Seasons Hotel – Washington, DC

Panel Discussion: Patient Navigation (Spring 2023 Cancer Policy Roundtable)

NCCS’s bi-annual Cancer Policy Roundtable (CPR) convenes stakeholders in the cancer community to discuss pressing issues related to cancer research, development of new cancer therapies, and the delivery of quality cancer care. Participants include cancer survivors, advocates, providers, payers, researchers, government officials, and industry representatives.

Follow a manual added linkFollow a manual added link

Meeting Agenda

Note: All times Eastern. Session times subject to change.

  • 8:30 AM – Registration and Breakfast
  • 9:00 AM – Survivor Perspective
  • 9:30 AM – New Directions and New Providers in Cancer Care
    Panel Discussion

    • This panel will explore emerging trends in cancer care delivery, examining the expanding ecosystem of providers beyond traditional oncology practices. The discussion will focus on how various entities — from care networks to supportive care organizations — are reshaping service delivery, care coordination, and patient experience, while addressing key questions about system transparency, quality improvement, and cost management.
  • 10:30 AM – Break
  • 10:45 AM – Expanding Access to Supportive Care
    • Together for Supportive Cancer Care is a national coalition that will work to expand early, equitable access to whole-person, supportive care for all people with cancer, regardless of where they receive care.

      Susan Hedlund, MSW, LCSW
      Director, Supportive Care Initiative
      The Les and Sheri Biller Family Foundation

  • 11:15 AM – The Promise and Pitfalls of Artificial Intelligence in Cancer Care
    Panel Discussion

    • This panel discussion will explore how artificial intelligence is transforming cancer diagnosis, treatment planning, and patient care, from accelerating drug discovery to improving the accuracy of medical imaging analysis. The session will examine both the exciting potential of AI to enhance clinical decision-making and patient outcomes, as well as critical challenges around data quality, algorithmic bias, clinical validation, and the evolving role of health care providers.
  • 12:15 PM – Lunch
  • 1:15 PM – Trends in Utilization Management and Prior Authorization
    Panel Discussion

    • This panel will explore evolving approaches to managing health care costs and quality through utilization review processes and prior authorization requirements. The discussion will examine emerging technologies, policy changes, and operational strategies that payers and providers are implementing to streamline authorization workflows while ensuring appropriate care delivery.
  • 2:15 PM – Break
  • 2:30 PM – Closing Keynote

Background Reading

To help you prepare for the meeting, we have assembled some background reading material about the topics that will be covered in the sessions, including:

  • 2024 Election Results
  • Cancer Care Reimbursement
  • 340B Drug Program
  • PBMs
  • Drug Price Negotiation

Speaker Biographies

Kimryn Rathmell, MDKimryn Rathmell, MD, PHD, MMHC
Director, National Cancer Institute

W. Kimryn Rathmell, MD, PhD, MMHC, was sworn in as the 17th NCI director on December 18, 2023. She previously led the Vanderbilt University Medical Center as physician-in-chief and chair of the Department of Medicine.

Dr. Rathmell has held leadership positions with the American Society of Clinical Oncology and the American Society for Clinical Investigation, serving as secretary–treasurer and president. As a result of her efforts, Dr. Rathmell has been elected to the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.

Dr. Rathmell’s specialty is the research and treatment of complex and hereditary kidney cancers. She also focuses on underlying drivers of kidney cancers using genetic, molecular, and cell biology to develop interventions to improve patients’ lives. Dr. Rathmell’s research has resulted in more than 250 articles in leading peer-reviewed journals, including The New England Journal of Medicine, Nature, Proceedings of the National Academy of Sciences, and the Journal of Clinical Investigation.

Read More About Dr. Rathmell on NCI’s Website »

Elizabeth CarpenterElizabeth Carpenter
Executive Vice President, Policy and Research
Pharmaceutical Research and Manufacturers of America (PhRMA)

Elizabeth Carpenter serves as executive vice president of policy and research for the Pharmaceutical Research and Manufacturers of America (PhRMA).

Elizabeth joins PhRMA from Avalere, where she spent 10 years, most recently as President. Prior to joining Avalere, Elizabeth was a senior advisor in the Health Policy practice at McKenna Long & Aldridge LLP, where she provided government affairs and public policy support to payers, providers, private exchanges, and states on a wide-range of health policy and political issues. Previously, she served as the associate policy director for the Health Policy Program at the New America Foundation where she led Congressional and media relations during the debate over the ACA and provided educational and technical support to stakeholders, members of Congress, and the media. Elizabeth started her career on Capitol Hill on the legislative and campaign staffs of Senator Lincoln Chafee (RI).

Debra CurtisDebra Curtis
McDermott+ Consulting

Debra Curtis is a highly-respected health policy authority who helps clients advance their missions in Congress and beyond. With more than three decades of experience working both on the Hill and with the health insurance exchange marketplace, she helps clients execute payment strategy, see around the corner on policy and regulatory changes, and pursue effective advocacy. In addition, Debbie has deep experience working closely with payers, industry stakeholders and government officials at the federal, state and local levels.

During her 24 years as a Congressional Staffer, Debbie served most recently in a joint position as Chief of Staff to US Representative Pete Stark (D-CA), and as a professional staff member on the US House of Representatives Committee on Ways & Means, Health Subcommittee. Debbie was integrally involved in the creation and movement of health legislation through the committee, with a focus on improving and protecting Medicare. She was a key staffer in the development of the Affordable Care Act, and worked closely with the Administration and other Congressional committees and Leadership on the implementation of the law.

Debbie joins McDermott+ from the DC Health Benefit Exchange Authority, where she was part of the founding team that established and operated DC Health Link, the District of Columbia’s online state-based health insurance exchange marketplace. In that capacity, she worked closely with stakeholders, advocates and government officials at the local and federal levels and led the Authority’s interactions with the Centers for Medicare and Medicaid Services.

Shelley Fuld NassoShelley Fuld Nasso, MPP
Chief Executive Officer
National Coalition for Cancer Survivorship (NCCS)

As Chief Executive Officer, Shelley Fuld Nasso leads the public policy activities of NCCS at a time of rapid and fundamental health care system change. Shelley joined NCCS in December 2012 and was named CEO in October 2013.

Prior to joining NCCS, Shelley served in leadership roles at Susan G. Komen, where she leveraged Komen’s grassroots network in Washington, D.C., and in state capitals. There she built relationships with policymakers and partner organizations and led a team of staff and volunteer leaders to influence state budgets and legislation. Under her leadership, Komen successfully secured $80 million in state funding for cancer screening and treatment for uninsured and under-insured women. She and her team also expanded the Komen grassroots advocacy program from a pilot of seven affiliates to more than 100 affiliates across the country engaged in federal and state advocacy efforts. Shelley has also served as Director of Community Philanthropy at The Dallas Foundation and held management positions at communications and technology enterprises. She is a graduate of Rice University and holds a Master of Public Policy from the Harvard Kennedy School.

Shelley’s commitment to the work of NCCS is strongly tied to the experiences in the cancer care system of her dear friend, Dr. Brent Whitworth, a beloved physician who was diagnosed with stage IV cancer days before his 42nd birthday and who passed away 19 months later. Through Brent’s experiences, Shelley witnessed the strengths and flaws of the cancer care system and embraces the notion that policy change can make cancer care better for patients and caregivers. Shelley and her husband Michael live in Maryland and are the parents of three young boys.

Social Media Toolkit

We encourage speakers and participating organizations to engage with NCCS on social media throughout the Fall 2024 Cancer Policy Roundtable. Please contact NCCS Communications and Marketing Manager Kara Kenan at kkenan@canceradvocacy.org with any questions or concerns.

Engage with NCCS on social media by:

  • Following us.
  • Taking photos. Please email Kara Kenan (kkenan@canceradvocacy.org) photos you’d like shared by NCCS.
  • Posting about sessions throughout the day, including posts using the sample copy below.
  • Like, share, and comment on NCCS social media posts.
  • Using the hashtags below.

NCCS’s social media handles:

Hashtags

  • #CPR24
  • #cancersurvivorship
  • #canceradvocacy

Sample Social Posts

We have provided some sample posts below for each social platform.

X
Joining @CancerAdvocacy’s #CPR24 today! Grateful for this space to address policy challenges in #cancerpolicy and quality care. Looking forward to the discussions! #canceradvocacy

I’m proud to represent [organization] at @CancerAdvocacy’s Fall 2024 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR24

Thank you, @CancerAdvocacy, for hosting the Fall 2024 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR24


LinkedIn
Participating in @NCCSCancerAdvocacy’s Cancer Policy Roundtable with policy experts, advocates, and researchers. Looking forward to today’s agenda, which includes discussions with leaders in cancer care and health policy. Ready for impactful conversations! #CPR24 #canceradvocacy

I’m proud to represent [organization] at the @NCCSCancerAdvocacy’s Fall 2024 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR24

Thank you, @NCCSCancerAdvocacy, for hosting the Fall 2024 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR24


Instagram
Excited to attend @cancersurvivorship’s #CPR24 Cancer Policy Roundtable! From #cancerpolicy to quality care, today’s sessions bring together leaders to drive change in #cancersurvivorship.

I’m proud to represent [organization] at @cancersurvivorship’s Fall 2024 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR24

Thank you, @cancersurvivorship, for hosting the Fall 2024 Cancer Policy Roundtable. I’m excited for the future


Facebook
At @cancersurvivorship’s Cancer Policy Roundtable today with leaders in #cancerresearch and #cancerpolicy. Looking forward to today’s sessions, which includes discussions leaders in cancer care and health policy. Ready for impactful conversations! #CPR24 #canceradvocacy

I’m proud to represent [organization] at @cancersurvivorship’s Fall 2024 Cancer Policy Roundtable. Great insights into the future of cancer care. #CPR24

Thank you, @cancersurvivorship, for hosting the Fall 2024 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR24

X
Honored to participate in @CancerAdvocacy’s #CPR24, gathering top experts to address policy needs in #cancersurvivorship, #cancerresearch, and access to care. Let’s drive change together.

Thank you, @CancerAdvocacy, for inviting me to speak at today’s Fall 2024 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR24


LinkedIn
Excited to contribute to @NCCSCancerAdvocacy’s #CPR24 Cancer Policy Roundtable. Today’s discussions with leaders in cancer care and health policy are vital for advancing #cancerresearch and #cancerpolicy for quality care.

Thank you, @NCCSCancerAdvocacy, for inviting me to speak at today’s Fall 2024 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR24


Instagram
Proud to speak at @cancersurvivorship’s #CPR24 Cancer Policy Roundtable! Exploring the future of #cancerpolicy with leaders in health and research. Together, we can make a difference. #cancersurvivorship

Thank you, @cancersurvivorship, for inviting me to speak at today’s Fall 2024 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR24


Facebook
Honored to join leaders in cancer care and health policy at @cancersurvivorship’s #CPR24 Cancer Policy Roundtable to discuss the future of #cancerresearch and policy changes needed to support #cancersurvivorship. Let’s make strides toward quality care and accessibility.

Thank you, @cancersurvivorship, for inviting me to speak at today’s Fall 2024 Cancer Policy Roundtable. I’m excited for the future of cancer care. #CPR24

Registration Form

We have reached capacity for this event.

If you were invited to attend and have questions about registering, please contact Elena Jeannotte at ejeannotte@canceradvocacy.org.

  • How would you prefer your name to appear on your name badge?


  • Please let us know about any special considerations or accommodations that you might need for attending CPR in-person.
  • Questions?
    Please contact Nadine Dorvelus at ndorvelus@canceradvocacy.org.


Please contact Nadine Dorvelus at ndorvelus@canceradvocacy.org with any questions you may have.

Cancer Policy Roundtable Fall 2024

(as of 10/1/2024)

CPR Spring 2024 Sponsors upper tier: Genentech, Gilead Oncology, Merck, Novartis, Pfizer

2024 Fall CPR Sponsor Logos: Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Eisai, Genmab, Janssen Pharmaceuticals, Lilly, Pharmacyclics, PhRMA, Sanofi